The common pathophysiology underlying the metabolic syndrome,
schizophrenia and depression. A review

J 2015

The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review

KUČEROVÁ, Jana, Zuzana BABINSKÁ, Kateřina HORSKÁ a Hana KOTOLOVA

Základní údaje

Originální název

The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review

Autoři

KUČEROVÁ, Jana (203 Česká republika, garant, domácí), Zuzana BABINSKÁ (703 Slovensko, domácí), Kateřina HORSKÁ (203 Česká republika) a Hana KOTOLOVA (203 Česká republika)

Vydání

Biomedical Papers, Olomouc, Palacký University, 2015, 1213-8118

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 0.924

Kód RIV

RIV/00216224:14110/15:00082177

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.5507/bp.2014.060

UT WoS

000359128900007

Klíčová slova anglicky

metabolic syndrome; schizophrenia; depression; sex/gender differences; adipokines; leptin; adiponectin; resistin; AFABP

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 13. 7. 2020 10:03, Mgr. Tereza Miškechová

Anotace

V originále

Background. There is a growing interest in metabolic alterations in patients with psychiatric disorders due to their increased risk for metabolic syndrome (MetS) development. Inflammation is known to underlie the pathophysiology of schizophrenia and depression as well as MetS. Vulnerability factors for schizophrenia/depression and MetS hence appear to be shared. Methods and Results. Based on a Web of Science search, this review examines current evidence for MetS pathophysiology involving dysregulation of adipose tissue signaling – adipokines and pro-inflammatory cytokine, both also known to be aberrant in schizophrenia/depression. Further, gender differences in the incidence and course of schizophrenia/depression were reported. The disturbances linked to the MetS are also described. Therefore, this review further maps the gender differences in the psychiatric-metabolic comorbidities. Conclusion. There is evidence supporting a pathological predisposition to MetS in both schizophrenia and depression in both humans and animal models. This predisposition is dramatically enhanced by antipsychotic medication. Further, there are gender differences from clinical findings suggesting women with schizophrenia/depression are more vulnerable to MetS development. This has not yet been assessed in animal studies. We suggest further validation of existing schizophrenia and depression animal models for the assessment of metabolic disturbances to provide tools for developing new antipsychotics and antidepressants with “metabolically inert” profile or improving the metabolic status in schizophrenic/depressed patients.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

MUNI/A/0886/2013, interní kód MU

Název: Farmakodynamické, farmakokinetické a farmakogenetické přístupy v preklinické fázi výzkumu a vývoje léčiv (Akronym: FDN, FKK a FGEN studie)

Investor: Masarykova univerzita, Farmakodynamické, farmakokinetické a farmakogenetické přístupy v preklinické fázi výzkumu a vývoje léčiv, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

KUČEROVÁ, Jana, Zuzana BABINSKÁ, Kateřina HORSKÁ a Hana KOTOLOVA. The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review. Biomedical Papers. Olomouc: Palacký University, 2015, roč. 159, č. 2, s. 208-214. ISSN 1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2014.060.

@article{1210779,
   author = {Kučerová, Jana and Babinská, Zuzana and Horská, Kateřina and Kotolova, Hana},
   article_location = {Olomouc},
   article_number = {2},
   doi = {http://dx.doi.org/10.5507/bp.2014.060},
   keywords = {metabolic syndrome; schizophrenia; depression; sex/gender differences; adipokines; leptin; adiponectin; resistin; AFABP},
   language = {eng},
   issn = {1213-8118},
   journal = {Biomedical Papers},
   title = {The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review},
   url = {https://biomed.papers.upol.cz/pdfs/bio/2015/02/07.pdf},
   volume = {159},
   year = {2015}
}

TY  - JOUR
ID  - 1210779
AU  - Kučerová, Jana - Babinská, Zuzana - Horská, Kateřina - Kotolova, Hana
PY  - 2015
TI  - The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review
JF  - Biomedical Papers
VL  - 159
IS  - 2
SP  - 208-214
EP  - 208-214
PB  - Palacký University
SN  - 12138118
KW  - metabolic syndrome
KW  - schizophrenia
KW  - depression
KW  - sex/gender differences
KW  - adipokines
KW  - leptin
KW  - adiponectin
KW  - resistin
KW  - AFABP
UR  - https://biomed.papers.upol.cz/pdfs/bio/2015/02/07.pdf
L2  - https://biomed.papers.upol.cz/pdfs/bio/2015/02/07.pdf
N2  - Background. There is a growing interest in metabolic alterations in patients with psychiatric disorders due to their increased risk for metabolic syndrome (MetS) development. Inflammation is known to underlie the pathophysiology of schizophrenia and depression as well as MetS. Vulnerability factors for schizophrenia/depression and MetS hence appear to be shared. Methods and Results. Based on a Web of Science search, this review examines current evidence for MetS pathophysiology involving dysregulation of adipose tissue signaling – adipokines and pro-inflammatory cytokine, both also known to be aberrant in schizophrenia/depression. Further, gender differences in the incidence and course of schizophrenia/depression were reported. The disturbances linked to the MetS are also described. Therefore, this review further maps the gender differences in the psychiatric-metabolic comorbidities. Conclusion. There is evidence supporting a pathological predisposition to MetS in both schizophrenia and depression in both humans and animal models. This predisposition is dramatically enhanced by antipsychotic medication. Further, there are gender differences from clinical findings suggesting women with schizophrenia/depression are more vulnerable to MetS development. This has not yet been assessed in animal studies. We suggest further validation of existing schizophrenia and depression animal models for the assessment of metabolic disturbances to provide tools for developing new antipsychotics and antidepressants with “metabolically inert” profile or improving the metabolic status in schizophrenic/depressed patients.
ER  -

KUČEROVÁ, Jana, Zuzana BABINSKÁ, Kateřina HORSKÁ a Hana KOTOLOVA. The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review. \textit{Biomedical Papers}. Olomouc: Palacký University, 2015, roč.~159, č.~2, s.~208-214. ISSN~1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2014.060.

Podrobný výpis o publikaci